growth s t u d i e s . This was i n v e s t i g a t e d by performing 12 consecutive weekly knemometric s e s s i o n s (each c o n s i s t i n g of 6 measurements)
and 4-weekly stadiometry on 31 h e a l t h y c h i l d r e n of 6-12.5 y e a r s Of age. The average SD of 6 measurements was 0.12 mm. A r e g r e s s i o n ( l i n e a r and 4 orthogonal polynomials) was computed of 1.1.1. on time. The r e s i d u a l mean square was much higher than t h e variance within 6 measurements. The l i n e a r r e g r e s s i o n was s i g n i f i c a n t a t 0.05 l e v e l i n 29 c h i l d r e n . Average (LSD) 1.1.1. growth v e l o c i t y was 0.36t0.14 mm/week, and h e i g h t 1.27r0.54 mm/week (ratio 3.9t2.0).
The 2nd. 3rd, and 4 t h polynomials were s i g n i f i c a n t more o f t e n than expected i f h i g h e r o r d e r e f f e c t s would be absent. When growth vel o c i t i e s were c a l c u l a t e d over t h e f i r s t 6 weeks (v ) and l a s t 6 weeks ( v 2 ) , v and v were d i f f e r e n t from zero i n h3 and 19 c h i ldren. Mean t AD of t z e 31 v v a l u e s were 0.39 and 0.15 -/week. was s i g n i f i c a n t l y d i f h e r e n t from z e r o i n 5 c h i l d r e n . Mean + :bk t h e 31 v2-vI v a l u e s were -0.05lr0.23 -/week. I f a one-side t e s t i s used, a difference v2-v1 g r e a t e r than 0.37 mm/week i s s i gn i f i c a n t . This corresponds wlth a s t a t u r a l growth response of 7. U . of Cadiz ( S p a i n ) and Zurich ( S w i t z e r l a n d ) .
ARGUMENTAL-MODULE

METHOD FOR THE STUDY OF BONE AGE (BA)
The most accepted numerical method for t h e assessment of BA i s Tanner -Whitehouse (TWZ). However, i t s d i s a d v a ntage i s t h a t i t i s laborious and r e q u i r e s t r a i n e d s t a f f . A method based on computer a n a l y s i s of bone s h a p e a s indicator of maturity h a s been d e v e l o p e d . The r e p r e s e n t a t i -
v e p a t t e r n s of each maturity stage of t h e TW2 a t l a s have been d i g i t i z e d b y means of a g r a p h i c b o a r d . The computer calculates t h e g r a v i t y center of t h e figures and r e p r e s e n t e s t h e vectorial r a d i u s from t h e center of g r a v i t y t o t h e point of t h e bone perimeter f o r each d i g i t i z e d point on
a coordinate a x i s . The degrees of each vector (0-360Q) correspond t o a x i s X and t h e length of each vector to a x i s Y . The unified e x t r e m e s of t h e v e c t o r s r e s u l t in a r e p r e s e n t a t i v e c u r v e of t h e bone s h a p e . The comparison of a problem c u r v e with t h e catalogue of s t a n d a r d c u r v e s of TW2 a t l a s h a s demonstrated t h a t t h i s method i s e a s i e r t h a n t h e c l a s s i c method.
The (IC= integrated concentration; AUC= area under the curve) Fasting serum IGF-1 levels were elevated in 2 girls aged 11 (37 nM/1) and 15 yrs (48 nM/l), and within the normal range in the rest of the sibs (16-43 nM/l), and in the parents (16.5 & 24.2 nM/l), with a si nificant correlation to their basal GH levels (r=.85, p< .02Q.
In conclusion, the pattern of GH secretion in several members of a family with tall stature was reported. In all the siblings an abnormal GH response to TRH and in 3 tested an increased daily output of GH was found. wide range of the GH results most probably reflects physiological variations in this age group. Our results are essentially negative. Moreover. the concept. that bromocriptine reduces GH secretion. seems doubtful: in 6 of our patients we have measured plasma GH after 2.5 mg of bromocriptine and found a significant increase within the first three hours.
Our results do not support the data from the literature. We conclude. that bromocriptine is ineffective in reducing adult height of tall girls and boys. Supported by Swiss National Science Foundation grant 3.906.083. (HP-TWII) , respectively. To substantiate these findings, each patient was pair-matched with a control, an untreated boy with a height above +2SDS and a bone age differing less than 0.5 yr. HP-BP was significantly reduced in patients after 1 yr of BRC compared with their matched controls after 1 yr of follow-up (p less than 0.02). By contrast, differences in HP-TWII were not significant. Because of this discrepancy it is uncertain whether final height in tall boys will really be reduced by treatment with BRC. BRC was kindly provided by Dr. R. Schmidt, Sandoz Ltd.
